CADL offering history
Every offering-related filing in Candel Therapeutics, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 416 filings back to Feb 16, 2021.
| Date | Filing | What it means | |
|---|---|---|---|
| Feb 20, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 19, 2026 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Oct 14, 2025 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Aug 22, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Aug 14, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jun 24, 2025 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 13, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 12, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 24, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 13, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Aug 12, 2022 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Aug 5, 2022 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jul 28, 2021 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Jul 26, 2021 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jul 26, 2021 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jul 21, 2021 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jul 16, 2021 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| Jun 25, 2021 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes — EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
CADL offering FAQ
When did CADL last execute an offering?
Per SEC filings, Candel Therapeutics, Inc.'s most recent priced offering document is a 424B5 filed 2026-02-20. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did CADL last announce or register an offering?
The most recent registration is a S-3 filed 2025-08-14. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.